| Testing<br>Labcorp    | bcorp<br>will be performed at a<br>baborator, including<br>y branded Dianon Pathology.   | Dianon Systems, Inc.<br>1 Forest Parkway<br>Shelton, CT 06484<br>800-328-2666<br>203-926-7100                                  | GI PATHOLOGY SERVICES<br>TEST REQUISITION   | Jar 21                | -   |
|-----------------------|--|--|---|-----------------------|---|
| AC                    | COUNT INFORMATION  |  | PATIENT INFORMATION   |                       |   |
|                       | COUNT NO. TELEF  | PHONE NO.  | CHART NUMBER PATIENT D.O.B.   | 9                     | Name  |
|                       |  |  | PATIENT LAST NAME FIRST NAME M.I. STREET ADDRESS  | Jar 17 Site           |   |
|                       | UESTING PHYSICIAN (PLEASE PRINT)   | PHYSICIAN/AUTHORIZED SIGNATURE   | CITY STATE ZIP CODE   |                       |   |
|                       | UESTING PHYSICIAN NPI  | REFERRING PHYSICIAN (PLEASE PRINT)   | RACE MRN / PATIENT ID# PATIENT TELEPHONE NO.  |                       |   |
|                       | Diag   | nosis/Signs/Symptoms in ICD-CM format in effect at   | t Date of Service (Highest Specificity Required) REQUIRED ICD-CM CODE(5):   | Site _                | Name  |
| BILL                  | .:   | MEDICARE 🗌 MEDICAID 🗌 INSURANCE 🗌  |   | 13 0                  |   |
|                       |  |  | 2 <sup>ND</sup> INS POLICY/ID# GROUP #  | Jar 1                 | Lt 1d   |
|                       |  |  | INSURANCE CARRIER   |                       |   |
|                       |  |  | CLAIM ADDRESS STATE ZIP   |                       |   |
| PAT                   | TENT HOSPITAL STATUS □ INPATIENT □   | OUTPATIENT 🗆 NON-PATIENT   | INSURED'S NAME INSURED'S DOB  |                       |   |
|                       |  |  | PATIENT'S RELATIONSHIP TO INSURED: SPOUSE CHILD OTHER   | Ð                     | Name  |
|                       | ECIMEN COLLECTION  |  |   | Site                  |   |
| ME                    |  |  | COLLECTION DATE://  | Jar 9                 | lar 10  |
| E.                    |  | DOLYPECTOMY OTHER  | COLLECTION DATE://  | Ъ<br>б                |   |
| 1<br>2                | EROSION 4 MASS<br>ERYTHEMA 5 NODULARITY<br>GRANULARITY 6 NORMAL<br>CLINICAL DATA (Check all that a<br>BLEEDING   | 7 POLYP 10 STRIC<br>8 POLYPOSIS 11 ULCE<br>9 PSEUDOMEMBRANE 12 BARR<br>pply)<br>ANOREXIA REFLUX<br>NAUSEA WEIGHT LOSS          | R 14 OTHER  | Site                  | Name<br>Site  |
|                       |  | 4  | CONSULTATION: On referred slides (Send pathology report) CONSULTATION: On referred material requiring slide prep (Send pathology report)  f Separately billable stains may be added by pathologist when medically necessary to render a diagnosis.  ESOPHAGUS  TYPE BODY SITE/ ENDOSCOPIC EINDINGS  | Jar 5                 |   |
| U<br>P<br>E<br>R<br>G | Other:   | ☐ Rule Out Fungi<br>☐ Rule Out Viral Inclusions<br>☐ Rule Out Reflux Esophagitis<br>☐ Rule Out Eosinophilic Esophagitis        | SPECIMEN         Solution         Sector         Sec   | Jar 1 Site            | Name  |
| I                     | OTHER TESTS (see reverse for CP  | T Codes Billed)  | STOMACH / DUODENUM  |                       |   |
|                       | <ul> <li>□ 180836 H. pylori Urea Breath Test</li> <li>□ 180764 H. pylori Stool Antigen</li> <li>□ 511345 Hereditary Hemochromatosis,</li> <li>□ 550123 HCV FibroSure® @%</li> <li>□ 550960 NASH FibroSure® Plus @%*</li> </ul> |  | TYPE     BODY SITE/     TENDOSCOPIC       DESCRIPTOR     TENDOSCOPIC       SPECIMEN     Statistics     Statistics       #     B     B     B       B     B     B     B   |                       | le  |
|                       | 550180 ASH FibroSure® @%*     *Required for ASH/NASH:     Fasting at least 8 hours? Yes     Other:   | No Height (ins) Weight (lbs)   |   | Site                  | n. Site   |
|                       | CLINICAL DATA (Check all that a  |  | LOWER GI TEST REQUEST <sup>+</sup>  | su                    | in forn   |
|                       | BLEEDING  DIARRHEA (BLOODY)  DIARRHEA (WATERY)  WEIGHT LOSS  PAIN  A   | FAMILY HISTORY OF CANCER     (TYPE)     PERSONAL HISTORY OF CANCER     (TYPE)     PERSONAL HISTORY OF COLON POLYPS             | HISTOLOGY (Gross & Microscopic)         CYTOLOGY – BRUSHING         CYTOLOGY – WASHING         CYTOLOGY – OTHER         CONSULTATION: On referred slides (Send pathology report)  | Labeling Instructions | Complete all requested information on requisition form. |
| L                     |  | PERSONAL HISTORY OF IDIOPATHIC     INFLAMMATORY BOWEL DISEASE  | <ul> <li>CONSULTATION: On referred material requiring slide prep (Send pathology report)</li> <li>Histology <i>t</i> (Gross &amp; Microscopic Exam) with Reflex to Lynch Syndrome<br/>Comprehensive Tumor Evaluation* if meets Revised Bethesda criteria ◆</li> <li>Histology <i>t</i> (Gross &amp; Microscopic Exam) with Reflex to Lynch Syndrome<br/>Comprehensive Tumor Evaluation* if carcinoma or tubular adenoma at &lt;40</li> </ul>  | Labelin               | <ol> <li>Comple<br/>informa</li> </ol>                  |
| O<br>W                | SPECIAL INDICATIONS  |  | *Includes MLH1/MSH2/MSH6/PMS2 by IHC and/or MSI by PCR. If MLH1 is deficient, reflex to BRAF Gene Mutation; if negative, reflex to MLH1 Promoter Methylation#   |                       |   |
| E<br>R                | COLITIS SURVEILLANCE COLONOSCOPY  OULY/NEOPLASM SURVEILLANCE COLONOSCOPY  RULE OUT VIRAL INCLUSIONS  | RULE OUT IDIOPATHIC     INFLAMMATORY BOWEL DISEASE     RULE OUT CROHN'S     RULE OUT ULCERATIVE COLITIS     RULE OUT DYSPLASIA | BODY SITE DESCRIPTOR ENDOSCOPIC   |                       |   |
| G<br>I                | RULE OUT PARASITES     RULE OUT MICROSCOPIC COLITIS     OTHER:     BIOPSY/EXCISION DATA     ANAL FISSURE   | C RULE OUT MALIGNANCY  | single |                       |   |
|                       | ANAL FISTULA<br>ANAL TAG<br>APPENDECTOMY (NON-INCIDENTA  | 1)   |   |                       |   |

+

1A

1B

Jar 23

Name\_

Site

19

Jar

Name\_

15

Jar

Name\_

Jar 11

Name\_

Name\_

Name\_

Place the indicated label on the corresponding specimen jar. Use one label per specimen.
 Discard all unused labels.

сi

ю<sup>.</sup>

ო Jar

Jar 7

Jar 24

Name\_

20

Jar

Name\_

Name\_

Name\_

Name\_

Name\_

For Questions, Contact Client Services at 1-800-328-2666.

Jar 4

Jar 8

42

Jar

16 Jar Name.

Name\_

Name.

Name\_

Name.

Name

+

1A

1B

Refer to Determining Necessity of ABN Completion on reverse.
 @ = Subject to Medicare medical necessity guidelines
 % = Subject to Medicare frequency guidelines
 # = Medicare deems investigational

**OTHER TESTS** 

) ANAL FISTULA ) ANAL FISTULA ) ANAL TAG ) APPENDECTOMY (NON-INCIDENTAL) ) CHOLECYSTECTOMY 1 HEMORRHOIDS LIVER BIOPSY

\_cm When ordering tests for which Medicare or Medicaid reimbursement will be sought, physicians should order only those tests that are medically necessary for the diagnosis or treatment of the patient. WHITE COPY TO DIANON PINK COPY TO PHYSICIAN

\_ cm

\_ cm

Lynch Syndrome Eval performed and billed by Labcorp Oncology.

© 2023 Laboratory Corporation of America® Holdings

(1369) REV. 12/21/2023

CT Lic. #: CL-0356

## **Test Combination/Panel Policy**

Labcorp's policy is to provide physicians, in each instance, with the flexibility to choose appropriate tests to assure that the convenience of ordering test combinations/panels does not distance physicians who wish to order a test combination/profile from making deliberate decisions regarding which tests are truly medically necessary. All the tests offered in test combinations/panels may be ordered individually using the Labcorp request form. Labcorp encourages clients to contact their local Labcorp representative or Labcorp location if the testing configurations shown here do not meet individual needs for any reason, or if some other combination of procedures is desired.

In an effort to keep our clients fully informed of the content, charges and coding of its test combinations/panels when billed to Medicare, we periodically send notices concerning customized test combinations/panels, as well as information regarding patient fees for all Labcorp services. We also welcome the opportunity to provide, on request, additional information in connection with our testing services and the manner in which they are billed to physicians, health care plans, and patients.

The CPT code(s) listed are in accordance with the current edition of *Current Procedural Terminology*, a publication of the American Medical Association. CPT codes are provided for the convenience of our clients; however, correct coding often varies from one carrier to another. Consequently, the codes presented here are intended as general guidelines and should not be used without confirming with the applicable payor that their use is appropriate in each case. All laboratory procedures will be billed to third-party carriers (including Medicare and Medicaid) at fees billed to patients and in accordance with the specific CPT coding required by the carrier. Microbiology CPT code(s) for additional procedures such as susceptibility testing, identification, serotyping, etc. will be billed in addition to the primary codes when appropriate. Labcorp will process the specimen for a Microbiology test based on source.

| nponents<br>na-2 Macroglobulin<br>toglobin<br>lipoprotein A-1<br>ubin, Total<br>T %@<br>* (SGPT)                                      | <b>CPT Code(s)</b><br>83883<br>83010<br>82172<br>82247<br>82977<br>84460  | Hereditary Hemoch<br>CPT Code: 81256  | romatosis, DNA Analysis  | Test No. 511345   |  |  |
|---|---|---|--|---|--|--|
| na-2 Macroglobulin<br>toglobin<br>lipoprotein A-1<br>ubin, Total<br>Γ%@   | 83883<br>83010<br>82172<br>82247<br>82977   |   |  |   |  |  |
| toglobin<br>lipoprotein A-1<br>ubin, Total<br>Γ %@  | 83010<br>82172<br>82247<br>82977  |   |  |   |  |  |
|   |   |   |  |   |  |  |
| NASH FibroSure®         Test No. 55           CPT Codes: 83883, 83010, 82172, 82247, 82977, 84460, 82465, 84478, 82947, 84450         |   |   | ASH FibroSure®         Test No. 550180           CPT Codes: 83883, 83010, 82172, 82247, 82977, 84460, 82465, 84478, 82947, 84450   |   |  |  |
| nponents  | CPT Code(s)   | When ordered<br>Individually<br>use Test No.  | Components   | CPT Code(s)   |  |  |
| na-2 Macroglobulin<br>toglobin<br>lipoprotein A-1<br>ubin, Total<br>T %@<br><sup>•</sup> (SGPT)<br>lesterol, Total %@<br>lycerides %@ | 83883<br>83010<br>82172<br>82247<br>82977<br>84460<br>82465<br>84478<br>82947   | 122135<br>001628<br>016873<br>001099<br>001958<br>001545<br>001065<br>001172<br>001032  | Alpha-2 Macroglobulin<br>Haptoglobin<br>Apolipoprotein A-1<br>Bilirubin, Total<br>GGT %@<br>ALT (SGPT)<br>Cholesterol, Total %@<br>Triglycerides %@<br>Glucose %@  | 83883<br>83010<br>82172<br>82247<br>82977<br>84460<br>82465<br>84478<br>82947<br>84450  |  |  |
| li<br>li  | -<br>a-2 Macroglobulin<br>opglobin<br>poprotein A-1<br>bin, Total<br>%@<br>(SGPT)<br>esterol, Total %@<br>rcerides %@<br>ose %@ | a-2 Macroglobulin       83883         oglobin       83010         poprotein A-1       82172         bin, Total       82247         %@       82977         (SGPT)       84460         esterol, Total %@       82465         rcerides %@       84478         ose %@       82947 | ponents         CPT Code(s)         use Test No.           a-2 Macroglobulin         83883         122135           boglobin         83010         001628           poprotein A-1         82172         016873           bin, Total         82247         001099           %@         82977         001958           (SGPT)         84460         001545           besterol, Total %@         82465         001065           ccerides %@         84478         001172           base %@         82947         001032 | ponents         CPT Code(s)         use Test No.         Components           a-2 Macroglobulin         83883         122135         Alpha-2 Macroglobulin           boglobin         83010         001628         Haptoglobin           poporotein A-1         82172         016873         Apolipoprotein A-1           bin, Total         82247         001099         Bilirubin, Total           %@         82977         001958         GGT %@           (SGPT)         84460         001545         ALT (SGPT)           esterol, Total %@         82465         001065         Cholesterol, Total %@           rcerides %@         84478         001172         Triglycerides %@ |  |  |

 Revised Bethesda guidelines for testing colorectal tumors for MSI: Colorectal cancer diagnosed in a patient who is <50 years of age, or Colorectal cancer with the MSI-H histology diagnosed in a patient who is <60 years of age.</li>

# Determining Necessity of Advance Beneficiary Notice of Non-coverage (ABN) Completion\*

1. Diagnose. Determine your patient's diagnosis.

2. **Document.** Write the diagnosis code(s) on the front of this requisition.

3. Verify. Determine if the laboratory test(s) ordered for the patient is subject to Local Coverage Determination or National Coverage Determination. This information can be located in the policies published by your Medicare Administrative Contractor (MAC), CMS, or www.Labcorp.com/MedicareMedicalNecessity.

4. **Review.** If the diagnosis code for your patient <u>does not</u> meet the medical necessity requirements set forth by Medicare or the test(s) is being performed more frequently than Medicare allows, an ABN should be completed.

\*An ABN should be completed for all tests that are considered investigational (experimental or for research use) by Medicare.

### How to Complete an Advance Beneficiary Notice of Non-coverage (ABN)

Medicare is very specific in requiring that all of the information included on the ABN be completed. Additionally, Labcorp requests that the specimen number or bar code label be included on the form. To be valid an ABN must:

- 1. Be executed on the CMS approved ABN form (CMS-R-131)
- 2. Identify the Medicare Part B Beneficiary, using the name as it appears on the patient's red, white and blue Medicare card
- 3. Indicate the test(s)/procedure(s) which may be denied within the relevant reason column
- 4. Include an estimated cost for the test(s)/procedure(s) subject to the ABN
- 5. Have 'Option 1', 'Option 2', or 'Option 3' designated by the beneficiary
- 6. Be signed and dated by the beneficiary or his/her representative prior to the service being rendered

## Symbols used to designate Medicare medical review as of 01/01/2024

#### @ = Subject to Medicare medical necessity guidelines

- % = Subject to Medicare frequency guidelines
- # = Medicare deems investigational. Medicare does not pay for services it deems investigational.

labcorp

Dianon Systems, Inc. is a subsidiary of Laboratory Corporation of America Holdings, using the brand Labcorp